Robert Schmouder

Novartis (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index6.7kcitations109works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sphingolipid Metabolism and Signaling(34), Renal Transplantation Outcomes and Treatments(27), Complement system in diseases(19), Drug Transport and Resistance Mechanisms(11), Pharmacological Effects and Toxicity Studies(9)

Publications109 total

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
British Journal of Pharmacology·2026Open Access
Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction–Associated Steatohepatitis
Alimentary Pharmacology & Therapeutics·2025· 2 citedOpen Access
Assessment of <scp>QT</scp> Interval Prolongation Using Concentration– <scp>QT</scp> Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals
Clinical and Translational Science·2025· 1 citedOpen Access
WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-&lt;30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
Kidney International Reports·2025Open Access
Effect of Target‐Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function
Clinical Pharmacology & Therapeutics·2025· 1 citedOpen Access
Multiple Supratherapeutic Doses of Iptacopan 400 Mg Twice Daily Are Well Tolerated in Healthy Participants: Safety Findings from a Randomized, Participant-Blinded, Placebo-Controlled, Phase I Study
Blood·2024· 1 cited
Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to &lt;30 mL/min: Phase 3 APPLAUSE-IgAN Subcohort Results
Journal of the American Society of Nephrology·2024· 1 cited
WCN24-550 SINGLE DOSE OF IPTACOPAN TREATMENT RAPIDLY DESCREASES PLASMA COMPLEMENT Bb LEVELS
Kidney International Reports·2024Open Access
WCN24-748 ASSESSMENT OF THE EFFECT OF HEPATIC IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS
Kidney International Reports·2024Open Access
WCN24-555 PHARMACOKINETICS OF SINGLE DOSES OF IPTACOPAN
Kidney International Reports·2024Open Access
WCN24-750 ASSESSMENT OF DRUG INTERACTIONS WITH IPTACOPAN
Kidney International Reports·2024Open Access
Results of Preclinical Animal Studies to Evaluate the Effect of Iptacopan on Pregnancy-Related Outcomes
Blood·2023· 1 citedOpen Access
A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101)
Blood·2023· 2 citedOpen Access
A Phase 1 Study to Evaluate the Pharmacokinetics of Single High Doses of Iptacopan
Blood·2023· 4 cited
A Phase 1 Study to Assess the Effect of Supratherapeutic Doses of Iptacopan on Cardiac Conduction Parameters and Safety
Blood·2023· 5 cited
Exposure-Response Relationships between the Factor B Inhibitor Iptacopan and Complement Biomarkers in Healthy Volunteers and Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 Glomerulopathy (C3G) or IgA Nephropathy (IgAN)
Blood·2023· 5 cited
#4447 EFFECT OF RENAL IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS
Nephrology Dialysis Transplantation·2023· 3 citedOpen Access
#4463 JAPANESE AND WHITES SHARE SIMILAR IPTACOPAN PHARMACOKINETICS AND PHARMACODYNAMICS
Nephrology Dialysis Transplantation·2023· 1 citedOpen Access
#3278 HUMAN PHARMACOKINETICS OF MULTIPLE, STEADY-STATE DOSING OF IPTACOPAN
Nephrology Dialysis Transplantation·2023· 5 citedOpen Access
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab
Science Translational Medicine·2023· 32 cited
page 1 of 6Next →

Frequent Co-authors

John M. Kovarik(16), Gilles‐Jacques Rivière(7), Klemens Budde(6), Andrej Skerjanec(5), Olivier David(4), Yibin Wang(4), Marie‐Claude Bastien(4), D. Beyer(4), Hélio Tedesco‐Silva(4), Franck Picard(4), Akinlolu Ojo(3), Robert A. Wolfe(3), Philip J. Held(3), Friedrich K. Port(3), Alan B. Leichtman(3), Robert M. Strieter(3), Thomas L. Hunt(3), Torsten Böhler(3), M. N. Bizot(3), Qiudi Jiang(3)